Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

NVCR – NovoCure Limited

NovoCure Limited
NVCR
$15.58
Name : NovoCure Limited
Sector : Healthcare
Industry: Medical Devices
Mark. Cap: $1,712,475,648.00
EPSttm : -1.56
finviz dynamic chart for NVCR
NovoCure Limited
$15.58
1.58%
$0.25

Float Short %

5.51

Margin Of Safety %

Put/Call OI Ratio

0.12

EPS Next Q Diff

0.13

EPS Last/This Y

-0.42

EPS This/Next Y

-0.03

Price

15.58

Target Price

34.29

Analyst Recom

1.57

Performance Q

-40.12

Relative Volume

0.81

Beta

0.77

Ticker: NVCR




22 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-03-20NVCR19.180.1420.4925509
2025-03-21NVCR19.340.120.0424983
2025-03-24NVCR19.760.150.0212373
2025-03-25NVCR18.770.140.1713716
2025-03-26NVCR18.440.141.3313856
2025-03-27NVCR18.960.140.8013961
2025-03-28NVCR18.840.150.0614101
2025-03-31NVCR17.830.150.3414124
2025-04-01NVCR17.520.150.1214295
2025-04-02NVCR17.930.150.0014335
2025-04-03NVCR16.990.150.1614365
2025-04-04NVCR16.480.141.0314481
2025-04-07NVCR16.670.140.2514576
2025-04-08NVCR15.360.140.4814627
2025-04-09NVCR17.070.140.2614676
2025-04-10NVCR16.080.140.0014936
2025-04-11NVCR16.470.140.2714927
2025-04-14NVCR16.560.140.3214903
2025-04-15NVCR16.440.140.0615006
2025-04-16NVCR15.810.140.0515100
2025-04-17NVCR15.570.120.1414938
2025-04-18NVCR15.580.120.1414938
DateSymbolLastP/C OIP/C VolTotal OI
22 items Current Page1 of 1




22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-03-20NVCR19.18-37.0-128.5-2.04
2025-03-21NVCR19.36-37.0-133.3-2.04
2025-03-24NVCR19.78-37.0-137.3-2.04
2025-03-25NVCR18.77-37.0-115.9-2.04
2025-03-26NVCR18.44-37.0-125.5-2.04
2025-03-27NVCR18.97-37.0-138.9-2.04
2025-03-28NVCR18.86-37.0-129.0-2.04
2025-03-31NVCR17.82-37.0-114.7-2.04
2025-04-01NVCR17.52-37.0-125.5-2.04
2025-04-02NVCR17.94-37.0-137.6-2.04
2025-04-03NVCR16.98-37.0-114.9-2.04
2025-04-04NVCR16.50-37.0-122.3-2.04
2025-04-07NVCR16.65-37.0-133.5-2.04
2025-04-08NVCR15.37-37.0-108.4-2.04
2025-04-09NVCR16.97-37.0-161.6-2.04
2025-04-10NVCR16.09-37.0-115.8-1.98
2025-04-11NVCR16.50-27.8-138.4-1.97
2025-04-14NVCR16.55-27.8-131.5-1.97
2025-04-15NVCR16.46-27.7-129.0-1.97
2025-04-16NVCR15.82-27.7-119.1-1.97
2025-04-17NVCR15.58-27.7-125.8-1.97
2025-04-18NVCR15.58-27.7-130.6-1.98
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1




22 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-03-20NVCR-0.40-1.245.30
2025-03-21NVCR-0.40-1.245.30
2025-03-24NVCR-0.40-1.355.30
2025-03-25NVCR-0.40-1.355.30
2025-03-26NVCR-0.40-1.355.49
2025-03-27NVCR-0.40-1.355.49
2025-03-28NVCR-0.40-1.355.49
2025-03-31NVCR-0.40-1.355.49
2025-04-01NVCR-0.40-1.355.49
2025-04-02NVCR-0.40-1.355.49
2025-04-03NVCR-0.40-1.355.49
2025-04-04NVCR-0.40-1.355.49
2025-04-07NVCR-0.40-1.345.49
2025-04-08NVCR-0.40-1.345.49
2025-04-09NVCR-0.40-1.345.49
2025-04-10NVCR-0.40-1.345.51
2025-04-11NVCR-0.40-1.345.51
2025-04-14NVCR-0.40-1.365.51
2025-04-15NVCR-0.40-1.365.51
2025-04-16NVCR-0.40-1.365.51
2025-04-17NVCR-0.40-1.365.51
2025-04-18NVCR-0.40-1.365.51
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
22 items Current Page1 of 1

Last Quarter Act. EPS

-0.61

Avg. EPS Est. Current Quarter

-0.49

Avg. EPS Est. Next Quarter

-0.48

Insider Transactions

-0.4

Institutional Transactions

-1.36

Beta

0.77

Average Sales Estimate Current Quarter

147

Average Sales Estimate Next Quarter

150

Fair Value

Quality Score

41

Growth Score

43

Sentiment Score

4

Actual DrawDown %

93.3

Max Drawdown 5-Year %

-95.1

Target Price

34.29

P/E

Forward P/E

PEG

P/S

2.83

P/B

4.69

P/Free Cash Flow

EPS

-1.56

Average EPS Est. Cur. Y​

-1.98

EPS Next Y. (Est.)

-2.01

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-27.86

Relative Volume

0.81

Return on Equity vs Sector %

-66.8

Return on Equity vs Industry %

-65

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.06

EBIT Estimation

-130.6
NovoCure Limited
Sector: Healthcare
Industry: Medical Devices
Employees: 1488
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
stock quote shares NVCR – NovoCure Limited Stock Price stock today
news today NVCR – NovoCure Limited stock forecast ,stock prediction 2023 2024 2025
marketwatch NVCR – NovoCure Limited yahoo finance google finance
stock history NVCR – NovoCure Limited invest stock market
stock prices NVCR premarket after hours
ticker NVCR fair value insiders trading